Latest Regulatory Filings News

Coronado Global Resources has filed a detailed SEC Form 8-K revealing confidential discussions with noteholders and outlining its growth trajectory, liquidity management, and operational updates across its Australian and US metallurgical coal assets.

EMVision Medical Devices has expanded its pivotal clinical trial sites, secured a $3 million government grant, and raised $14 million through placement and share purchase plan, positioning itself strongly for upcoming regulatory submissions and commercialisation.

New Frontier Minerals reports significant progress in its Harts Range and NWQ Copper projects, revealing new heavy rare earth prospects and promising copper recovery results that could accelerate production timelines.

MCS Services Limited reported a $644k cash outflow from operations in Q1 2025 while lodging multiple traffic management tenders and exploring growth strategies. The company continues to consider selling its Traffic Business subsidiary, Highways Traffic Pty Ltd.

Premier1 Lithium Limited’s PLCO securities have been suspended from trading due to regulatory non-compliance, raising questions about the company’s next steps and market impact.

Aguia Resources Limited’s AGRO securities have been suspended from trading by ASX Compliance, pending regulatory compliance. The move raises questions about the company’s current standing and next steps.

Australis Oil & Gas reported a mixed Q3 2025 with lower production volumes offset by higher oil prices, achieving modest profitability and reducing debt while actively seeking a development partner for its Tuscaloosa Marine Shale assets.

Avecho Biotechnology has raised $2.5 million from institutional investors to fast-track manufacturing and regulatory preparations for its CBD TPM capsule amid ongoing Phase III trials.

Firebrick Pharma reports a $1.94 million cash reserve after a $1.4 million placement, supporting expanded Nasodine sales across Southeast Asia and the US. Board changes and increased operational costs mark a pivotal quarter for the pharmaceutical innovator.

Rent.com.au reports a surge in recurring revenues driven by strong RentBond® loan growth, doubling monthly revenue run rates and advancing towards profitability.

Imricor Medical Systems made significant regulatory strides with FDA submissions for its MRI-guided cardiac ablation devices and launched NorthStar commercially in Europe, even as it reported increased cash outflows in Q3 CY25.

TrivarX has completed recruitment of 60 patients in its US veteran-focused mental health trial, advancing validation of its novel single-lead ECG algorithm for depression screening. Positive interim results from 27 patients set the stage for full data release and commercial discussions.